{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:47:14Z","timestamp":1792597634509,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003645","name":"National Cancer Center","doi-asserted-by":"publisher","award":["NCC-2310570"],"award-info":[{"award-number":["NCC-2310570"]}],"id":[{"id":"10.13039\/501100003645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003645","name":"National Cancer Center","doi-asserted-by":"publisher","award":["NCC-24H1220"],"award-info":[{"award-number":["NCC-24H1220"]}],"id":[{"id":"10.13039\/501100003645","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"DOI":"10.1186\/s40644-026-01095-9","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:14:47Z","timestamp":1784906087000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical impact of PSMA PET\/CT on the management of biochemical recurrence in prostate cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Sohyun","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Sung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Uk","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhu Quang","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Young","family":"Joung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-ki","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"issue":"3","key":"1095_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"1095_CR2","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","volume":"87","author":"EJ Schafer","year":"2025","unstructured":"Schafer EJ, Laversanne M, Sung H, Soerjomataram I, Briganti A, Dahut W, et al. Recent patterns and trends in global prostate cancer incidence and mortality: An update. Eur Urol. 2025;87(3):302\u201313.","journal-title":"Eur Urol"},{"issue":"2","key":"1095_CR3","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41391-023-00712-z","volume":"27","author":"ND Shore","year":"2024","unstructured":"Shore ND, Moul JW, Pienta KJ, Czernin J, King MT, Freedland SJ. Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification. Prostate Cancer Prostatic Dis. 2024;27(2):192\u2013201.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"1095_CR4","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/JU.0000000000003892","volume":"211","author":"TM Morgan","year":"2024","unstructured":"Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, et al. Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline Part I: Introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy. J Urol. 2024;211(4):509\u201317.","journal-title":"J Urol"},{"key":"1095_CR5","doi-asserted-by":"crossref","unstructured":"Sciarra A, Santarelli V, Salciccia S, Moriconi M, Basile G, Santodirocco L, et al. How the management of biochemical recurrence in prostate cancer will be modified by the concept of anticipation and incrementation of therapy. Cancers (Basel). 2024;16(4).","DOI":"10.3390\/cancers16040764"},{"issue":"1","key":"1095_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","volume":"22","author":"MK Bakht","year":"2025","unstructured":"Bakht MK, Beltran H. Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer. Nat Rev Urol. 2025;22(1):26\u201345.","journal-title":"Nat Rev Urol"},{"key":"1095_CR7","doi-asserted-by":"crossref","unstructured":"Handa N, Bennett Rt, Li EV, Ho A, Huang MM, Kumar S, et al. PSMA PET\/CT findings in high-risk biochemical recurrence after local treatment of prostate cancer. BJUI Compass. 2025;6(5).","DOI":"10.1002\/bco2.70028"},{"issue":"2","key":"1095_CR8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.eururo.2025.05.006","volume":"88","author":"E Mazzone","year":"2025","unstructured":"Mazzone E, Thomson A, Chen DC, Cannoletta D, Quarta L, Pellegrino A, et al. The role of prostate-specific membrane antigen positron emission tomography for assessment of local recurrence and distant metastases in patients with biochemical recurrence of prostate cancer after definitive treatment: a systematic review and meta-analysis. Eur Urol. 2025;88(2):129\u201341.","journal-title":"Eur Urol"},{"issue":"2","key":"1095_CR9","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s00259-023-06438-3","volume":"51","author":"S Adebahr","year":"2024","unstructured":"Adebahr S, Althaus A, Scharl S, Strouthos I, Farolfi A, Serani F, et al. The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy. Eur J Nucl Med Mol Imaging. 2024;51(2):558\u201367.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10231","key":"1095_CR10","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208\u201316.","journal-title":"Lancet"},{"issue":"1","key":"1095_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s40644-024-00752-1","volume":"24","author":"S Harsini","year":"2024","unstructured":"Harsini S, Martineau P, Plaha S, Saprunoff H, Chen C, Bishop J, et al. Prognostic significance of a negative PSMA PET\/CT in biochemical recurrence of prostate cancer. Cancer Imaging. 2024;24(1):117.","journal-title":"Cancer Imaging"},{"issue":"9","key":"1095_CR12","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.2967\/jnumed.121.263521","volume":"63","author":"M Ng","year":"2022","unstructured":"Ng M, Guerrieri M, Wong LM, Taubman K, Sutherland T, Benson A, et al. Changes in management after (18)F-DCFPyL PSMA PET in patients undergoing postprostatectomy radiotherapy, with early biochemical response outcomes. J Nucl Med. 2022;63(9):1343\u20138.","journal-title":"J Nucl Med"},{"key":"1095_CR13","doi-asserted-by":"publisher","first-page":"102987","DOI":"10.1016\/j.canep.2026.102987","volume":"101","author":"J Jung","year":"2026","unstructured":"Jung J, Kang H, Choo E, Kang HY, Jeong CW, Jeon HL, et al. Prostate cancer in Korea: Nationwide trends in prevalence and medication use during 2011\u20132021. Cancer Epidemiol. 2026;101:102987.","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"1095_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.prnil.2015.06.003","volume":"3","author":"HH Han","year":"2015","unstructured":"Han HH, Park JW, Na JC, Chung BH, Kim CS, Ko WJ. Epidemiology of prostate cancer in South Korea. Prostate Int. 2015;3(3):99\u2013102.","journal-title":"Prostate Int"},{"issue":"5","key":"1095_CR15","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s13139-025-00946-w","volume":"59","author":"M Suh","year":"2025","unstructured":"Suh M, O JH. Bridging the Gap: PSMA Radioligand Therapy for Asian Men with Prostate Cancer. Nucl Med Mol Imaging. 2025;59(5):342\u201350.","journal-title":"Nucl Med Mol Imaging"},{"key":"1095_CR16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.bbrc.2023.02.003","volume":"651","author":"MH Kim","year":"2023","unstructured":"Kim MH, Lee K, Oh K, Kim CH, Kil HS, Lee YJ, et al. Evaluation of PSMA target diagnostic PET tracers for therapeutic monitoring of [(177)Lu]ludotadipep of prostate cancer: Screening of PSMA target efficiency and biodistribution using [(18)F]DCFPyL and [(68)Ga]PSMA-11. Biochem Biophys Res Commun. 2023;651:107\u201313.","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"1095_CR17","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.3346\/jkms.2010.25.9.1291","volume":"25","author":"JY Joung","year":"2010","unstructured":"Joung JY, Cho KS, Chung HS, Cho IC, Kim JE, Seo HK, et al. Prostate specific membrane antigen mRNA in blood as a potential predictor of biochemical recurrence after radical prostatectomy. J Korean Med Sci. 2010;25(9):1291\u20135.","journal-title":"J Korean Med Sci"},{"issue":"5","key":"1095_CR18","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/bju.13397","volume":"117","author":"PJ van Leeuwen","year":"2016","unstructured":"van Leeuwen PJ, Stricker P, Hruby G, Kneebone A, Ting F, Thompson B, et al. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU Int. 2016;117(5):732\u20139.","journal-title":"BJU Int"},{"key":"1095_CR19","doi-asserted-by":"crossref","unstructured":"Werner RA, Hartrampf PE, Fendler WP, Serfling SE, Derlin T, Higuchi T, et al. Eur Urol. 2023;84(5):491\u2013502. Prostate-specific Membrane Antigen Reporting and Data System Version 2.0.","DOI":"10.1016\/j.eururo.2023.06.008"},{"key":"1095_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.euros.2024.11.008","volume":"71","author":"S Thomas","year":"2025","unstructured":"Thomas S, Callahan J, Conway P, Moon D, Morgan H, Ingbritsen J, et al. High detection rates for prostate-specific membrane antigen-avid prostate cancer recurrence at Low Prostate-specific antigen levels on Extended Axial Field-of-view Positron Emission Tomography\/Computed Tomography. Eur Urol Open Sci. 2025;71:49\u201356.","journal-title":"Eur Urol Open Sci"},{"issue":"1","key":"1095_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3390\/diagnostics12010195","volume":"12","author":"MT Christensen","year":"2022","unstructured":"Christensen MT, Jochumsen MR, Klingenberg S, S\u00f8rensen KD, Borre M, Bouchelouche K. Evaluation of Predictors of Biochemical Recurrence in Prostate Cancer Patients, as Detected by 68Ga-PSMA PET\/CT. Diagnostics. 2022;12(1):195.","journal-title":"Diagnostics"},{"issue":"12","key":"1095_CR22","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.1007\/s00259-025-07292-1","volume":"52","author":"C Burgard","year":"2025","unstructured":"Burgard C, Frei M, Blickle A, Hartrampf PE, Hoffmann MA, Schreckenberger M, et al. PSMA PET\/CT in biochemical recurrence of prostate cancer with PSA levels\u2009\u2264\u20090.2 ng\/mL: a German multicenter analysis of conventional PSMA tracers, including [(68)Ga]Ga-PSMA-11, [(68)Ga]Ga-PSMA I&T, and [(18)F]PSMA-1007. Eur J Nucl Med Mol Imaging. 2025;52(12):4368\u201376.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1095_CR23","doi-asserted-by":"crossref","unstructured":"Rais-Bahrami S, Davis P, Chau A, Galgano SJ, Chapin BF, Schuster DM, et al. Detection Rates of PSMA-PET Radiopharmaceuticals in Recurrent Prostate Cancer: A Systematic Review. Diagnostics (Basel). 2025;15(10).","DOI":"10.3390\/diagnostics15101224"},{"issue":"6","key":"1095_CR24","doi-asserted-by":"publisher","first-page":"786","DOI":"10.2967\/jnumed.118.219501","volume":"60","author":"TA Hope","year":"2019","unstructured":"Hope TA, Goodman JZ, Allen IE, Calais J, Fendler WP, Carroll PR. Metaanalysis of (68)Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology. J Nucl Med. 2019;60(6):786\u201393.","journal-title":"J Nucl Med"},{"issue":"10","key":"1095_CR25","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1177\/02841851231184210","volume":"64","author":"YY Yang","year":"2023","unstructured":"Yang YY, Liu ZM, Peng RC. Diagnostic performance of 18F-labeled PSMA PET\/CT in patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis. Acta Radiol. 2023;64(10):2791\u2013801.","journal-title":"Acta Radiol"},{"issue":"2","key":"1095_CR26","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00259-020-04945-1","volume":"48","author":"WP Fendler","year":"2021","unstructured":"Fendler WP, Calais J, Eiber M, Simko JP, Kurhanewicz J, Santos RD, et al. False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial. Eur J Nucl Med Mol Imaging. 2021;48(2):501\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1095_CR27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/cancers17213404","volume":"17","author":"A Shamshirgaran","year":"2025","unstructured":"Shamshirgaran A, Samadi MH, Saeed M, Harsini S, Sahafi P, Divband G, et al. Fifty Shades of PSMA-Avid Rib Lesions: A Comprehensive Review. Cancers (Basel). 2025;17:21.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"1095_CR28","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s00259-017-3780-7","volume":"44","author":"S Sheikhbahaei","year":"2017","unstructured":"Sheikhbahaei S, Afshar-Oromieh A, Eiber M, Solnes LB, Javadi MS, Ross AE, et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Imaging. 2017;44(12):2117\u201336.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1095_CR29","doi-asserted-by":"crossref","unstructured":"Moukaddam H, El Saheb G, Omran N, El Ghawi N, Abi Ghanem A, Haidar M. Case report: positive pitfalls of PSMA PET\/CT: diagnostic challenges in degenerative bone lesions including MODIC type 1. Front Nuclear Med. 2024;4","DOI":"10.3389\/fnume.2024.1451848"},{"issue":"9","key":"1095_CR30","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1097\/MNM.0000000000001600","volume":"43","author":"A Bhoil","year":"2022","unstructured":"Bhoil A, Seshadri N, Vinjamuri S. Indeterminate skeletal and lymph node lesion on 18F PSMA 1007 PET\/CT scanning: lessons from a review at 12 months with PSMA-RADS. Nucl Med Commun. 2022;43(9):1034\u201341.","journal-title":"Nucl Med Commun"},{"issue":"5","key":"1095_CR31","doi-asserted-by":"publisher","first-page":"738","DOI":"10.2967\/jnumed.118.215434","volume":"64","author":"R Seifert","year":"2023","unstructured":"Seifert R, Telli T, Opitz M, Barbato F, Berliner C, Nader M, et al. Unspecific (18)F-PSMA-1007 Bone Uptake Evaluated Through PSMA-11 PET, Bone Scanning, and MRI Triple Validation in Patients with Biochemical Recurrence of Prostate Cancer. J Nucl Med. 2023;64(5):738\u201343.","journal-title":"J Nucl Med"},{"key":"1095_CR32","doi-asserted-by":"crossref","unstructured":"Liu F, Ge C, Qiao B, Aihemaiti Z, Li Z, Zhang W et al. PSMA-based theranostics in diagnosing and treating prostate cancer in the Asian male population: a narrative review. Front Oncol. 2025;15","DOI":"10.3389\/fonc.2025.1655082"},{"issue":"5","key":"1095_CR33","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41585-021-00442-8","volume":"18","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Mo M, Wei Y, Wu J, Pan J, Freedland SJ, et al. Epidemiology and genomics of prostate cancer in Asian men. Nat Reviews Urol. 2021;18(5):282\u2013301.","journal-title":"Nat Reviews Urol"},{"issue":"7801","key":"1095_CR34","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41586-020-2135-x","volume":"580","author":"J Li","year":"2020","unstructured":"Li J, Xu C, Lee HJ, Ren S, Zi X, Zhang Z, et al. A genomic and epigenomic atlas of prostate cancer in Asian populations. Nature. 2020;580(7801):93\u20139.","journal-title":"Nature"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-026-01095-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01095-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01095-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:02:41Z","timestamp":1792594961000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-026-01095-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1095"],"URL":"https:\/\/doi.org\/10.1186\/s40644-026-01095-9","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"12 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was reviewed and approved by the Institutional Review Board of the participating institution (approval No. NCC2026-0077). Owing to the retrospective design and the use of anonymized clinical and imaging data, the requirement for written informed consent was waived by the Institutional Review Board. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and applicable institutional regulations.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study used retrospectively collected and de-identified clinical data and PSMA PET\/CT images. All images included in the manuscript were presented in a manner that does not allow identification of individual patients.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"145"}}